Navigation Links
ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Date:8/27/2007

those caused by influenza virus), autoimmune disorders, certain medications (including most cytotoxic chemotherapy), radiation and bone marrow diseases such as leukemia or myelodysplastic syndromes. Replenishment of leukocytes at early time periods following irradiation could result from proliferation and maturation of a pluripotential stem cell subset that is protected from the damaging effect of radiation. Further studies are in process to delineate the mechanism of leukocyte replenishment.

About TGen

The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.

About Radilex(TM) and Viprovex(R)

Radilex(TM) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of exposure to ionizing radiation. Viprovex(R) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of viral and bacterial infections. Homspera(TM) is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.<
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, ... on the emerging field of regenerative medicine, today ... at Chicago -based Rush University ... evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte ... and motor complete cervical spinal cord injury (SCI). ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
(Date:8/31/2015)... ... August 31, 2015 , ... ... communications company announced today that it has officially launched a new website and ... website and brand refresh are more closely aligned with the company’s strategic vision ...
(Date:8/31/2015)... ... ... dental implant and prosthetic market in the U.S. is projected to reach $6.4 billion ... More than 30 million Americans are missing all their teeth in one or both ... National Association of Dental Laboratories (NADL) created the “What’s In Your Mouth?” campaign to ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad ... a ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of ... via AdvantaClean’s National Call Center and website since Aug. 17. , The Greens ...
(Date:8/31/2015)... ... ... Finnleo , a leader in the sauna industry, is pleased to announce ... re-styled and re-designed “Hallmark Series” updates the Passport series with a feature rich, portable ... and a more upscale feel than the current Passport a beautiful 6-bar two-toned curved ...
(Date:8/31/2015)... ... 31, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... Innovative Cancer Therapy for Tomorrow® meeting, is seeking abstract submissions for its ... City. The annual legacy meeting uses a variety of formats to educate all ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Finnleo Introduces Hallmark Series Saunas 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4
... Mayo Clinic researchers have discovered two mutations responsible for ... ago. The researchers say their study -- appearing in ... neural pathway that may help understand a variety of ... now because of Next Generation genomic sequencing technology," says ...
... , SATURDAY, April 30 (HealthDay News) -- After reviewing ... up to age 3, researchers found that about 4 percent ... higher among the youngest babies, the study found. "Almost ... 2 months, received more than twice the dose that they ...
... SUNDAY, May 1 (HealthDay News) -- Increased bursts of sleep in ... new study included 23 parents who kept daily sleep records for ... at the start of the study. The researchers analyzed the total ... The infants had uneven bursts of sleep, with the amount ...
... at extremely low levels, is associated with increased blood pressure ... 1, at the Pediatric Academic Societies (PAS) annual meeting in ... increased risk of having high blood pressure, or hypertension, as ... and kidney disease and is the third leading contributor to ...
... parent or caregiver to look in the rearview mirror while ... of their safety restraints. A study on child self-unbuckling by ... first unbuckle were age three and under and that many ... a 3.5-fold increased risk for serious injuries. , "We found ...
... study in the May 1 issue of the journal Sleep ... among infants are significantly associated with growth spurts in body length. ... 24-hour sleep duration increasing at irregular intervals by an average of ... sleep episodes per day also increased in intermittent bursts of an ...
Cached Medicine News:Health News:Mayo Clinic finds new genetic cause of neurodegeneration 2Health News:Young Kids' Prescriptions Not Always on the Mark 2Health News:Extra Sleep in Infants Seems to Signal Growth Spurts 2Health News:Living with a smoker may raise blood pressure in boys 2Health News:Little fingers, big trouble: Yale study sheds light on child self-unbuckling 2Health News:Study is the first to link sleep duration to infant growth spurts 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: